A flurry of six biotech deals launched last week from applied therapeutics, axcella health, cortxyme, nextcure and milestone pharmaceuticals. Each is looking to price on Wednesday, May 8 - testing the due dilligence capacity of buyside institutions. Milestone Pharmaceuticals' up-to-US$80m IPO presents a rare opportunity to invest in a late-stage biotech.
展开▼
